Cover Image
市場調查報告書

心律不整:開發平台分析

Arrhythmias - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 219844
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
心律不整:開發平台分析 Arrhythmias - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 55 Pages
簡介

所謂心律不整是心跳速度或頻律障礙。在心律不整期間心臟跳動會變得非常快、非常慢、或是不規律。症狀有不安、虛弱、暈眩、失去平衡感、失神或是快要失神、發汗、呼吸困難及胸口疼痛等。治療法有抗心律不整藥及抗凝固劑等。

本報告提供全球治療心律不整所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

心律不整概要

治療藥的開發

  • 心律不整開發中產品:概要
  • 心律不整開發中產品:比較分析

心律不整:各企業開發中的治療藥

心律不整:大學/研究機關研究中的治療藥

心律不整:開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

心律不整:開發中的產品一覽(各企業)

心律不整:研究中的產品一覽(大學/研究機關別)

心律不整的開發企業

  • Cynata Therapeutics Limited
  • Gilead Sciences, Inc.
  • 小野藥品工業
  • Orion Oyj
  • SciFluor Life Sciences, LLC
  • SignPath Pharma Inc

心律不整:治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • aladorian sodium
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome
  • efsevin
  • eleclazine
  • EU-8120
  • GS-967
  • KN-93
  • landiolol
  • LH-021
  • ORM-10103
  • PP-1
  • Small Molecule for Arrhythmia
  • Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia
  • Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure
  • Stem Cell Therapy for Cardiovacular Diseases
  • VKII-86

心律不整:開發中產品的最新趨勢

心律不整:開發暫停的產品

心律不整:開發中止的產品

心律不整相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8402IDB

Summary

Global Markets Direct's, 'Arrhythmias - Pipeline Review, H2 2016', provides an overview of the Arrhythmias pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arrhythmias
  • The report reviews pipeline therapeutics for Arrhythmias by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Arrhythmias therapeutics and enlists all their major and minor projects
  • The report assesses Arrhythmias therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Arrhythmias

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Arrhythmias
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Arrhythmias pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arrhythmias Overview
  • Therapeutics Development
    • Pipeline Products for Arrhythmias - Overview
    • Pipeline Products for Arrhythmias - Comparative Analysis
  • Arrhythmias - Therapeutics under Development by Companies
  • Arrhythmias - Therapeutics under Investigation by Universities/Institutes
  • Arrhythmias - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Arrhythmias - Products under Development by Companies
  • Arrhythmias - Products under Investigation by Universities/Institutes
  • Arrhythmias - Companies Involved in Therapeutics Development
    • Cynata Therapeutics Limited
    • Gilead Sciences, Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Orion Oyj
    • SciFluor Life Sciences, LLC
    • SignPath Pharma Inc
  • Arrhythmias - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aladorian sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • efsevin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eleclazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EU-8120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KN-93 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • landiolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LH-021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORM-10103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Arrhythmia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPP-4040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VKII-86 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Arrhythmias - Dormant Projects
  • Arrhythmias - Discontinued Products
  • Arrhythmias - Product Development Milestones
    • Featured News & Press Releases
      • May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Arrhythmias, H2 2016
  • Number of Products under Development for Arrhythmias - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Arrhythmias - Pipeline by Cynata Therapeutics Limited, H2 2016
  • Arrhythmias - Pipeline by Gilead Sciences, Inc., H2 2016
  • Arrhythmias - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Arrhythmias - Pipeline by Orion Oyj, H2 2016
  • Arrhythmias - Pipeline by SciFluor Life Sciences, LLC, H2 2016
  • Arrhythmias - Pipeline by SignPath Pharma Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Arrhythmias - Dormant Projects, H2 2016
  • Arrhythmias - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Arrhythmias, H2 2016
  • Number of Products under Development for Arrhythmias - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top